Oncolytic Viruses: A Viable Treatment Option for Treating Cancers
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5613Keywords:
Cancer Treatment, Immunotherapy, Oncolytic, Cancer, Tumor, Oncolytic Virus, Viral Therapy, MutationAbstract
Cancer is a disease that is based on the same principles that split species apart over time: evolution. Cancer cells have mutations in them that do not control cell proliferation, and the causes for cancer can come from different places; they could be hereditary or could be from environmental causes like toxic carcinogens. Either way, it is known that cancer is a problem that has been plaguing many species and is a main topic of study in humans. In these studies, new ideas for treatments have developed and even brought to the medical field as treatments, and one such treatment is the use of viruses in aiding to target and destroy cancer cells; these viruses are otherwise known as oncolytic viruses. The goal of this research paper is to evaluate a treatment option that aims to spare patients with cancer diagnoses from having healthy cells affected by the treatment option, something that is not currently offered in current cancer treatment options. This paper will research characteristics oncolytic viruses take advantage of and the mechanisms of these viruses used to target cancer cells. The paper will also investigate treatments that have been approved for treating specific cancers, and whether oncolytic viruses can serve as a viable treatment option to treat cancer soon based on current research done thus far.
Downloads
References or Bibliography
2A: Steps of Virus Infections. (2018). Biology LibreTexts. https://bio.libretexts.org/Bookshelves/Introductory_and_General_Biology/Book%3A_General_Biology_(Boundless)/21%3A_Viruses/21.02%3A_Virus_Infections_and_Hosts/21.2A%3A_Steps_of_Virus_Infections
Aurelian, L. (2013). Oncolytic virotherapy: the questions and the promise. Oncolytic Virotherapy, 19. https://doi.org/10.2147/ov.s39609
Buonaguro, F. M., Tornesello, M. L., Izzo, F., & Buonaguro, L. (2012). Oncolytic virus therapies. Pharmaceutical Patent Analyst, 1(5), 621–627. https://doi.org/10.4155/ppa.12.65
Cao, G. D., He, X. B., Sun, Q., Chen, S., Wan, K., Xu, X., Feng, X., Li, P. P., Chen, B., & Xiong, M. M. (2020). The Oncolytic Virus in Cancer Diagnosis and Treatment. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.01786
Champagne, J., Pataskar, A., Blommaert, N., Nagel, R., Wernaart, D., Ramalho, S., Kenski, J., Bleijerveld, O. B., Zaal, E. A., Berkers, C. R., Altelaar, M., Peeper, D. S., Faller, W. J., & Agami, R. (2021, November). Oncogene-dependent sloppiness in mRNA translation. Molecular Cell, 81(22), 4709-4721.e9. https://doi.org/10.1016/j.molcel.2021.09.002
Cook, M., & Chauhan, A. (2020). Clinical Application of Oncolytic Viruses: A Systematic Review. International Journal of Molecular Sciences, 21(20), 7505. https://doi.org/10.3390/ijms21207505
Fukuhara, H., Ino, Y., & Todo, T. (2016). Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Science, 107(10), 1373–1379. https://doi.org/10.1111/cas.13027
Hemminki, O., dos Santos, J. M., & Hemminki, A. (2020). Oncolytic viruses for cancer immunotherapy. Journal of Hematology & Oncology, 13(1). https://doi.org/10.1186/s13045-020-00922-1
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery, 14(9), 642–662. https://doi.org/10.1038/nrd4663
Kornepati, A. V. R., Vadlamudi, R. K., & Curiel, T. J. (2022). Publisher Correction: Programmed death ligand 1 signals in cancer cells. Nature Reviews Cancer, 22(3), 190–190. https://doi.org/10.1038/s41568-022-00445-6
Lathwal, A., Kumar, R., & Raghava, G. P. (2020). OvirusTdb: A database of oncolytic viruses for the advancement of therapeutics in cancer. Virology, 548, 109–116. https://doi.org/10.1016/j.virol.2020.05.016
Louten, J. (2016). Virus Replication. Essential Human Virology, 49–70. https://doi.org/10.1016/b978-0-12-800947-5.00004-1
Mechanisms of Oncolytic Virus Targeting Tumor Cells - Creative Biolabs. (n.d.). Mechanisms of Oncolytic Virus Targeting Tumor Cells - Creative Biolabs. https://www.creative-biolabs.com/oncolytic-virus/mechanisms-of-oncolytic-virus-targeting-tumor-cells.htm
New ‘don’t eat me’ signal may provide basis for cancer therapies. (2019). News Center. http://med.stanford.edu/news/all-news/2019/07/new-dont-eat-me-signal-may-provide-basis-for-cancer-therapies.html
Oncolytic Virus Kills Tumor Cells and Supports Immune Cells. (2019). National Cancer Institute. https://www.cancer.gov/news-events/cancer-currents-blog/2019/oncolytic-virus-improves-immune-cell-metabolism
Oncolytic Virus Therapy | Cancer Research Institute. (n.d.). Cancer Research Institute. https://www.cancerresearch.org/treatment-types/oncolytic-virus-therapy
Pessoa, J., Martins, M., Casimiro, S., Pérez-Plasencia, C., & Shoshan-Barmatz, V. (2022). Editorial: Altered Expression of Proteins in Cancer: Function and Potential Therapeutic Targets. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.949139
Programmed Death 1 Ligand 1 - an overview | ScienceDirect Topics. (n.d.). Programmed Death 1 Ligand 1 - an Overview | ScienceDirect Topics. https://doi.org/10.1016/j.clim.2021.108707
Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018). Oncolytic virus immunotherapy: future prospects for oncology. Journal for ImmunoTherapy of Cancer, 6(1). https://doi.org/10.1186/s40425-018-0458-z
Shi, T., Song, X., Wang, Y., Liu, F., & Wei, J. (2020). Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.00683
National Cancer Institute. (2002). The Genetics of Cancer. Retrieved from: https://www.cancer.gov/about-cancer/causes-prevention/genetics
Thomas, R., & Weihua, Z. (2019). Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Frontiers in Oncology, 9. https://doi.org/10.3389/fonc.2019.00800
Todo, T., Ino, Y., Ohtsu, H., Shibahara, J., & Tanaka, M. (2022). A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-31262-y
University of Washington. (2007). Cancer Cells More Likelty to Genetically Mutate. ScienceDaily. Retrieved August 18, 2023, from https://www.sciencedaily.com/releases/2007/02/070218194439.htm#:~:text=Summary%3A,regular%20cells%2C%20researchers%20have%20found
Yip, H. Y. K., & Papa, A. (2021). Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells, 10(3), 659. https://doi.org/10.3390/cells10030659
Yu, J., Wang, X., Teng, F., & Kong, L. (2016). PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy, Volume 9, 5023–5039. https://doi.org/10.2147/ott.s105862
Zhang, T., Jou, T. H. T., Hsin, J., Wang, Z., Huang, K., Ye, J., Yin, H., & Xing, Y. (2023). Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy. Journal of Clinical Medicine, 12(3), 1098. https://doi.org/10.3390/jcm12031098
Published
How to Cite
Issue
Section
Copyright (c) 2023 Rohit Rao; Rajagopal Appavu, Jothsna Kethar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
